Junshi Biosciences Reports P-III Clinical Trial Results of VV116 for Severe COVID-19
- The P-III trial results published in NEJM evaluating VV116 vs nirmatrelvir–ritonavir (PAXLOVID) in 822 COVID-19 adult patients
- As of data cut off Aug 2022, VV116 & PAXLOVID achieved noninferiority in the time to sustained clinical recovery in the FAS population, VV116 group had a shorter time to sustained clinical recovery (4 vs 5 days) with fewer safety concerns
- Similar results were seen in both groups i.e., time to sustained resolution of all target symptoms & time to a first negative SARS-CoV-2 test with a median time of 7 days., clinical recovery was larger in VV116 (Days 5, 7, 10, 14 & 28), the incidence of AEs (67.4% vs 77.3%), grade 3 or 4 AE (2.6% vs 5.7%), no participants in either group had died or had had progression to sev. COVID-19 by Day 28
Ref: Globenewswire | Image: Junshi Biosciences
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.